First Intranasal Covid-19 vaccine by Bharat Biotech gets DCGI approval


Imphal: Bharat Biotech has got emergency use authorisation from Drug Controller General of India (DCGI) for intranasal Covid-19 vaccine.

Union health minister Mansukh Mandaviya said this on Tuesday.

This will be India’s first nasal and needless vaccine for Covid-19 vaccine.

“Big Boost to India’s Fight Against COVID-19! Bharat Biotech’s ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation,” Mandaviya tweets.

Also Read:  National Tourism Day 2023

Bharat Biotech, according to its official website, is of the view that the new vaccine product can be scaled up to meet global demands.

“An intranasal vaccine stimulates a broad immune response – neutralizing IgG, mucosal IgA, and T cell responses. Immune responses at the site of infection (in the nasal mucosa) – (are) essential for blocking both infection and transmission of COVID-19,” the company said on its official website.

A total of 400 and 650 individuals participated in its Phase 1 and Phase 2 trials held last year.

Also Read:  Missing VDF personnel found dead

According to Bharat Biotech chairman and managing director Dr.Krishna Ella one dose of nasal vaccine could block the infection and thereby block the transmission chain and then can flatten the curve. It is just about 4 drops like Polio, 2 in one nostril and 2 in the other. Global authorities like the WHO are getting convinced about nasal as a second-generation vaccine.


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

error: Content Protected!